Related references
Note: Only part of the references are listed.First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
Dean Anthony Fennell et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial
Cornedine J. de Gooijer et al.
LANCET RESPIRATORY MEDICINE (2021)
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
S. Popat et al.
ANNALS OF ONCOLOGY (2020)
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays
David B. Chapel et al.
HUMAN PATHOLOGY (2019)
Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
Morihito Okada et al.
CLINICAL CANCER RESEARCH (2019)
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel et al.
LANCET ONCOLOGY (2019)
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma
Josine Quispel-Janssen et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
Michele Maio et al.
LANCET ONCOLOGY (2017)
Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma
Simone B. S. P. Terra et al.
ONCOIMMUNOLOGY (2017)
Novel insights into mesothelioma biology and implications for therapy
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2017)
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
Lee M. Krug et al.
LANCET ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
Susana Cedres et al.
PLOS ONE (2015)
B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
Aaron Scott Mansfield et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma
Justin Stebbing et al.
LUNG CANCER (2009)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A fixed sequence Bonferroni procedure for testing multiple endpoints
BL Wiens
PHARMACEUTICAL STATISTICS (2003)
Gemcitabine for malignant mesothelioma: A phase II trial by the cancer and leukemia group B
HL Kindler et al.
LUNG CANCER (2001)
Share Paper
